Septerna (SEPN) Research & Development (2023 - 2026)
Septerna (SEPN) posted quarterly Research & Development of $29.5 million for Q1 2026, up 53.26% year-over-year from $19.3 million in Q1 2025, and down 7.3% quarter-over-quarter from $31.9 million in Q4 2025.
Septerna (SEPN) Research & Development (2023 - 2026) Analysis & Trends
Septerna's Research & Development history runs 4 years deep, the most recent figure standing at $29.5 million for Q1 2026.
- In Q1 2026, Research & Development rose 53.26% year-over-year to $29.5 million; the TTM figure through Mar 2026 stood at $107.8 million (up 50.93% YoY), while the FY2025 annual figure was $97.6 million, up 49.35% from the prior year.
- Research & Development for Q1 2026 stood at $29.5 million, down from $31.9 million in the prior quarter.
- The five-year high for Research & Development was $31.9 million in Q4 2025, with the low at $9.3 million in Q3 2023.
- The 4-year median for Research & Development is $19.3 million (2025), against an average of $19.3 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development jumped 92.13% in 2024, then jumped 36.07% in 2025.
- Septerna's Research & Development stood at $10.3 million in 2023, then surged by 87.07% to $19.3 million in 2024, then soared by 64.94% to $31.9 million in 2025, then declined by 7.3% to $29.5 million in 2026.
- Business Quant data shows SEPN's Research & Development at $29.5 million in Q1 2026, $31.9 million in Q4 2025, and $24.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Septerna | 2.08 Bn | 2.08 Bn | - | 35.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.13 Mn |
| Mar 31, 2026 | 29.54 Mn |
| Dec 31, 2025 | 31.86 Mn |
| Sep 30, 2025 | 24.26 Mn |
| Jun 30, 2025 | 22.19 Mn |
| Mar 31, 2025 | 19.27 Mn |
| Dec 31, 2024 | 19.32 Mn |
| Sep 30, 2024 | 17.83 Mn |
| Jun 30, 2024 | 15.04 Mn |
| Mar 31, 2024 | 13.15 Mn |
| Dec 31, 2023 | 10.33 Mn |
| Sep 30, 2023 | 9.28 Mn |